Business Wire

INVENTIA-LIFE-SCIENCE

4.12.2023 10:01:33 CET | Business Wire | Press release

Share
Inventia Life Science Announces Third Dimension Grant for 3D Cell Culture Research

Inventia Life Science, a leading advanced cell model company, launched the Inventia Third Dimension Grant today. This grant will allow researchers studying fundamental biology or drug development to model and test hypotheses using 3D cell cultures. These advanced models enable scientists to test questions they’d be unable to answer using 2D cell cultures or animal models.

The Inventia Third Dimension Grant recipient will have Inventia’s RASTRUM benchtop device placed in their lab for three months. They’ll also receive all materials needed to generate at least six 96 or 384 well plates of 3D cell models.

RASTRUM is a high-throughput drop-on-demand bioprinter that can deposit cells and matrix components into common tissue culture microplates to form 3D cell cultures. Inventia opened a lab in Dublin last year to foster the use of advanced cell models throughout Europe.

“With 2D cell models or animal models, it’s impossible to conduct certain research that’s critical to the advancement of novel technologies,” says Daniel Vaughn, Inventia’s EU Commercial Director. “We expect the recipient of this grant to make great strides in their research — and to fully realise the opportunities that 3D models present for impactful breakthroughs — during the time they have the RASTRUM in their lab.”

Traditional 2D cell cultures and animal models lack the ability to accurately model human physiological interactions between tumours and their environment. With RASTRUM advanced cell models, scientists are able to design models that more precisely recreate those interactions allowing them to probe deeper into their field of study.

Application information

The Third Dimension Grant Program is open to academic and commercial laboratories not currently using the RASTRUM Platform in Europe. Applications are due before the 29th February 2024, and the recipient will be selected on 8th March 2024. Applicants should complete the submission form using the grant link.

About Inventia Life Science

Inventia is creating some of the most powerful tools for advanced biomedical discovery today. We build printers and formulate bioinks that, together, allow human cells to be printed in 3-dimensional structures and help forward-thinking pioneers in the fields of cancer research, drug discovery and medicine to create human tissue for research and therapy purposes. Our RASTRUM platform creates 3D cell cultures which imitate real human tissue in terms of structure and behaviour across a range of disease states. The physiological complexity of these cell cultures provides an environment in which world-class research and discovery can occur, right in the researcher’s own lab. Inventia Life Science was the vision of Dr. Julio Ribeiro and was founded by him with Dr. Aidan O'Mahony, Dr. Cameron Ferris and Peter Arthur in 2013. It is headquartered in Sydney, Australia.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20231205284641/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Expands Restylane® Portfolio in Japan With Launch of OBT™ Hyaluronic Acid Injectables Restylane Defyne™ and Refyne™11.2.2026 07:00:00 CET | Press release

Restylane® Refyne™ and Restylane Defyne™ are the first Optimal Balance Technology (OBT™) hyaluronic acid injectables ever approved and launched in Japan, bringing advanced flexibility and natural movement to the market1,2 This expands Galderma’s Restylane portfolio in Japan to four products, enabling treatment of a wider spectrum of patient and practitioner needs3,4 These two new launches underscore Galderma’s accelerating growth across the Japan & Asia Pacific (JPAC) region Galderma (SIX: GALD), the pure-play dermatology category leader, has announced the launch of Restylane Defyne and Restylane Refyne: the first OBT‑based hyaluronic acid injectables ever authorized in Japan.1,2 The products – designed for injection into the mid-to-deep dermis for the correction of moderate to severe facial wrinkles and folds – are now commercially available in the market.1,2 Restylane Defyne and Refyne leverage the unique balance of softness, flexibility, and support delivered by Galderma’s proprieta

Suzano Reports Record Sales and Continued Improvements in Operational Efficiency in 202511.2.2026 00:44:00 CET | Press release

Suzano, the world’s largest pulp producer, announces its results for both the final quarter (4Q25) and the full year (2025), reporting record annual sales volumes and net revenue. The company also reported an improvement in its cash cost of pulp production, reflecting the drive for improved operational efficiency. Pulp and paper sales reached 14.2 million tonnes, a 15% increase compared to 2024. This performance was driven primarily by the strong operational contribution of the Ribas do Rio Pardo pulp mill, which began production in July 2024, and the company’s paper mills in the United States. As a result, Suzano’s full‑year net revenue reached a record R$50 billion in 2025. The company’s consistent focus on efficiency and cost discipline also contributed to a meaningful reduction in the cash cost of pulp production. Excluding downtime, the annual cash cost was R$817 per tonne, reaching its lowest annual level since 2021. Operational efficiency also helped Suzano deliver operating cas

Eclipse Signs Partnership Agreement With BNP Paribas to Power the Next Stage of Growth11.2.2026 00:05:00 CET | Press release

The agreement includes a strategic equity investment in Eclipse by BNP Paribas Eclipse, a leading battery storage, development, and energy trading company, and BNP Paribas, one of the largest banks in the Eurozone, today announced a strategic partnership to accelerate the deployment of Battery Energy Storage Systems (BESS) and strengthen Europe's energy resilience. This partnership includes a strategic equity investment in Eclipse by BNP Paribas. Through its proprietary algo trading software, Flowstream, Eclipse optimizes battery energy storage assets in real-time for its own and third-party assets. As an integrated BESS player, Eclipse develops, owns, and operates industrial-scale energy assets. The company currently has a pipeline of 16 projects in France and Belgium, representing a total capacity of 850 MW. The partnership with BNP Paribas provides asset owners with tailored financing solutions for BESS projects, as well as hedging instruments to manage merchant risk and reduce asse

World Governments Summit 2027 Date Announced, Following Largest-Ever Global Participation10.2.2026 22:06:00 CET | Press release

Largest edition in the summit’s history convened 6,250+ global leaders, policymakers, and experts from 150+ countriesWorld leaders, including presidents from Switzerland, Sierra Leone, and beyond, lead strategic dialogues Under the leadership of UAE President His Highness Sheikh Mohamed bin Zayed Al Nahyan and His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, the World Governments Summit concluded in Dubai with its largest-ever participation, featuring more than 6,250 attendees. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260210283291/en/ World Governments Summit 2026 concludes in Dubai with record participation, bringing together more than 6,250 global leaders from over 150 countries to advance dialogue on governance, innovation, and sustainable development (Photo: AETOSWire) A Global Platform Convening Global Leaders Held in Dubai from 3 to 5 February, t

Palantir and Airbus Extend Strategic Collaboration10.2.2026 22:01:00 CET | Press release

Palantir Technologies (NASDAQ:PLTR) is proud to announce the extension of its collaboration with Airbus through a multi-year agreement, confirming a relationship that has driven innovation across the aerospace industry for over a decade. Under this renewed contract, Airbus will continue to rely on Palantir for Skywise, its civil aviation open data platform. The Skywise platform enhances aircraft and equipment designs and enables greater efficiency, safety and sustainability in the production of civil aircraft across the Airbus industrial footprint. It also improves the performance of airlines’ operations by combining in-flight engineering and operational data in an analytic rich environment enabling airlines to address their main challenges. This renewed commitment comes at a pivotal time, as the aerospace sector faces demands for innovation, agility, and competitiveness. With this renewed collaboration, Palantir will provide Airbus and its customers with continued access to cutting-ed

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye